Spots Global Cancer Trial Database for gemcitabine
Every month we try and update this database with for gemcitabine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease | NCT03770299 | Non-Small Cell ... Non-Small-Cell ... Circulating Tum... | Nivolumab Vinorelbine Gemcitabine Docetaxel Pemetrexed Cisplatin Carboplatin Paclitaxel Observation | 18 Years - | Bristol-Myers Squibb | |
| PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma | NCT04040491 | Peripheral T-ce... | PD-1 blocking a... | 14 Years - 65 Years | Zhengzhou University | |
| A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors | NCT06139211 | Advanced Solid ... | JS015 Toripalimab Paclitaxel Irinotecan Capecitabine Oxaliplatin Bevacizumab Fluorouracil Leucovorin Gemcitabine Albumin-Bound P... | 18 Years - 75 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT06161025 | Solid Cancer | R-DXd Gemcitabine Paclitaxel Topotecan PLD | 18 Years - | Daiichi Sankyo | |
| Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma | NCT01983969 | Advanced Cancer... Lymphoma | Azacitidine Vorinostat Gemcitabine Busulfan Melphalan Dexamethasone Caphosol Glutamine Pyridoxine Rituximab | 15 Years - 65 Years | M.D. Anderson Cancer Center | |
| Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer | NCT06196788 | Pancreatic Canc... | Gemcitabine Nab paclitaxel | 18 Years - 80 Years | Fudan University | |
| First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors | NCT04761601 | Advanced Solid ... | UCT-01-097 Gemcitabine Paclitaxel | 18 Years - | 1200 Pharma, LLC | |
| Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer | NCT05809895 | Triple Negative... | Ociperlimab Tislelizumab Paclitaxel Nab-paclitaxel Carboplatin Placebo Pembrolizumab Gemcitabine | 18 Years - | Novartis | |
| Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer | NCT04223856 | Urothelial Canc... | Enfortumab vedo... Pembrolizumab Cisplatin Carboplatin Gemcitabine | 18 Years - | Astellas Pharma Inc | |
| Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer | NCT00151034 | Urologic Neopla... | Trastuzumab Paclitaxel Carboplatin Gemcitabine | 18 Years - | University of Michigan Rogel Cancer Center | |
| Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | NCT04361409 | Head and Neck S... | Rituximab Cisplatin Gemcitabine | 20 Years - 65 Years | China Medical University Hospital | |
| Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS) | NCT02082522 | Hilar Cholangio... | Photodynamic th... Stenting proced... Chemotherapy re... | 18 Years - | Concordia Laboratories Inc. | |
| Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer | NCT03101566 | Biliary Tract N... | Gemcitabine Cisplatin Ipilimumab Nivolumab | 18 Years - | University of Michigan Rogel Cancer Center | |
| Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer | NCT05809895 | Triple Negative... | Ociperlimab Tislelizumab Paclitaxel Nab-paclitaxel Carboplatin Placebo Pembrolizumab Gemcitabine | 18 Years - | Novartis | |
| A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | NCT02423239 | Hepatocellular ... Pancreatic Canc... | Dexanabinol Sorafenib Nab-paclitaxel Gemcitabine | 18 Years - | e-Therapeutics PLC | |
| A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer | NCT01189929 | Pancreatic Canc... | Demcizumab Abraxane® Gemcitabine | 21 Years - | Mereo BioPharma | |
| Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma | NCT01233375 | Metastatic Panc... | CO-1.01 | 18 Years - | Clovis Oncology, Inc. | |
| Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas | NCT02037230 | Adenocarcinoma ... | MK-1775 Gemcitabine Radiation Thera... | 18 Years - | University of Michigan Rogel Cancer Center | |
| A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT04222972 | RET-fusion Non ... Lung Neoplasm Carcinoma, Non-... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Disea... Head and Neck N... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Germ... Neoplasms, Nerv... | Pralsetinib Carboplatin Cisplatin Pemetrexed Pembrolizumab Gemcitabine Paclitaxel Nab-Paclitaxel | 18 Years - | Hoffmann-La Roche | |
| Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT02272790 | Ovarian, Fallop... | Adavosertib Paclitaxel Carboplatin Gemcitabine PLD | 18 Years - 130 Years | AstraZeneca | |
| A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer | NCT04677504 | Biliary Tract C... | Atezolizumab Bevacizumab Placebo Cisplatin Gemcitabine | 18 Years - | Hoffmann-La Roche | |
| A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma | NCT05967182 | Cholangiocarcin... | Pembrolizumab Gemcitabine Cisplatin | 18 Years - | M.D. Anderson Cancer Center | |
| Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL. | NCT01670370 | Diffuse Large B... | R-GemOx | 60 Years - | The First Affiliated Hospital with Nanjing Medical University | |
| A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | NCT04408638 | Diffuse Large B... | Obinutuzumab Glofitamab Rituxumab Tocilizumab Gemcitabine Oxaliplatin | 18 Years - | Hoffmann-La Roche | |
| A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients | NCT02854072 | Pancreatic Canc... | GV1001 Gemcitabine Capecitabine | 19 Years - | Samsung Pharmaceutical Co., Ltd. | |
| A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma | NCT01472198 | Pancreatic Canc... | Simtuzumab Gemcitabine Placebo to matc... | 18 Years - | Gilead Sciences | |
| Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma | NCT00714948 | Bladder Cancer URINARY BLADDER | gemcitabine and... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers | NCT00626158 | Pancreatic Canc... Biliary Cancer | gemcitabine capecitabine | 18 Years - | University of California, San Francisco | |
| Multicenter Phase 2 Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell Lung Cancer | NCT00192036 | Non Small Cell ... | gemcitabine cisplatin radiation | 18 Years - | Eli Lilly and Company | |
| Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer | NCT00093795 | Breast Cancer | Cyclophosphamid... Docetaxel Gemcitabine Paclitaxel Doxorubicin | 18 Years - | NSABP Foundation Inc | |
| The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma. | NCT04045730 | Pancreas Adenoc... | Gemcitabine | 18 Years - | Yale University | |
| Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer. | NCT00471146 | Carcinoma, Panc... | AG-013736 Gemcitabine Gemcitabine placebo | 18 Years - | Pfizer | |
| Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC | NCT03629925 | Squamous NSCLC | Sintilimab Gemcitabine Cisplatin Placebo Carboplatin | 18 Years - 75 Years | Innovent Biologics (Suzhou) Co. Ltd. | |
| Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer | NCT03137771 | Recurrent Non-S... Stage IV Non-Sm... | 3-Dimensional C... Docetaxel Gemcitabine Intensity-Modul... Pemetrexed Diso... Stereotactic Bo... Erlotinib Hydro... Pembrolizumab | 18 Years - | NRG Oncology | |
| Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients | NCT00500422 | Solid Tumors | Doxil Gemcitabine Velcade | - | M.D. Anderson Cancer Center | |
| Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer | NCT02135822 | Advanced Pancre... | nanoparticle al... gemcitabine | 18 Years - | Chinese PLA General Hospital | |
| A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer | NCT06319820 | Non-Muscle Inva... | TAR-210 Gemcitabine MMC | 18 Years - | Janssen Research & Development, LLC | |
| Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma | NCT03984357 | Nasopharyngeal ... | PD-1 blocking a... Gemcitabine Cisplatin Intensity-modul... | 18 Years - 65 Years | Sun Yat-sen University | |
| Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer | NCT02996825 | Recurrent Breas... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Triple-Negative... | Gemcitabine Gemcitabine Hyd... Laboratory Biom... Mirvetuximab So... Pharmacological... | - | City of Hope Medical Center | |
| Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT00071136 | Lung Neoplasms | pemetrexed gemcitabine | 18 Years - | Eli Lilly and Company | |
| LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy | NCT02985125 | Metastatic Panc... | LEE011 Everolimus | 18 Years - | Georgetown University | |
| A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors | NCT05389462 | Advanced Solid ... | ADCT-601 Gemcitabine | 18 Years - | ADC Therapeutics S.A. | |
| Cervical Cancer Radiotherapy by Use of VMAT, Individualized Polyradiosensitization and Interstitial Brachytherapy | NCT02957266 | Cervical Cancer | Volumetric Arc ... Interstitial br... Cisplatin Gemcitabine PIK3CA KRAS BRAF RRM1 | 18 Years - 70 Years | The National Center of Oncology, Azerbaijan | |
| Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia | NCT02267707 | Pancreatic Neop... Cholestasis | nab-paclitaxel Gemcitabine | 18 Years - | Celgene | |
| A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma | NCT02539537 | Pancreatic Canc... Carcinoma | Gemcitabine Folinic Acid 5-Fluoro-uracil Oxaliplatin Irinotecan L-folinic | 18 Years - | UNICANCER | |
| A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer | NCT06233864 | Pancreatic Canc... | Disitamab Vedot... Gemcitabine | 18 Years - | Sun Yat-sen University | |
| A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma | NCT04833582 | Osteosarcoma | ZN-c3 Gemcitabine | 12 Years - | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | |
| Trial of Gemcitabine and Cisplatin in Patients With Inoperable Biliary Tract Carcinomas | NCT00490399 | Biliary Tract C... | gemcitabine cisplatin | 20 Years - 70 Years | Eli Lilly and Company | |
| Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer. | NCT00471146 | Carcinoma, Panc... | AG-013736 Gemcitabine Gemcitabine placebo | 18 Years - | Pfizer | |
| High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors | NCT00936936 | Testicular Canc... | Gemcitabine Docetaxel Melphalan Carboplatin Mesna Ifosfamide Etoposide Stem Cell Trans... | 12 Years - 65 Years | M.D. Anderson Cancer Center | |
| A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer | NCT00846027 | Breast Cancer | Bevacizumab Paclitaxel Gemcitabine | 18 Years - | Hoffmann-La Roche | |
| QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer | NCT00630552 | Adenocarcinoma ... Metastatic Panc... Pancreatic Canc... | Placebo AMG 479 AMG 655 | 18 Years - | NantCell, Inc. | |
| SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II | NCT04480372 | Malignant Pleur... Non-small Cell ... | Gemcitabine Atezolizumab | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer | NCT00705549 | Non-Small-Cell ... | Gemcitabine Cisplatin Docetaxel Cisplatin Vinorelbine Pemetrexate | 18 Years - | Hellenic Oncology Research Group | |
| Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer | NCT01860040 | Non-squamous Ce... Squamous Cell N... | Cisplatin Pemetrexed Gemcitabine | 18 Years - | Western Regional Medical Center | |
| Treatment of Pancreatic Cancer With Abraxane | NCT02555813 | Metastatic Panc... | Abraxane Gemcitabine | 18 Years - | Celgene | |
| Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval | NCT00657878 | Ovarian Cancer | stealth liposom... carboplatin paclitaxel Topotecan Gemcitabine | - | National Cancer Institute, Naples | |
| Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas | NCT00844649 | Metastatic Panc... | Albumin-bound p... Gemcitabine | 18 Years - 79 Years | Celgene | |
| Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma | NCT05738161 | Advanced Urothe... | Magrolimab Cisplatin Gemcitabine | 18 Years - | Insel Gruppe AG, University Hospital Bern | |
| Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer | NCT04498689 | Metastatic Panc... | Camrelizumab Nab paclitaxel Gemcitabine Inj... | 18 Years - 75 Years | Fudan University | |
| Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer | NCT05298020 | Advanced Pancre... | Envafolimab Endostar Nab paclitaxel Gemcitabine | 18 Years - | The Affiliated Hospital of Xuzhou Medical University | |
| Hepatic Artery Infusion Pump for NPC Liver Metastases | NCT03876574 | Nasopharyngeal ... Neoplasm Metast... Liver | DSA-guided impl... Gemcitabine Floxuridine dexamethasone | - | Xiangya Hospital of Central South University | |
| Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer | NCT00498225 | Pancreatic Canc... | Gemcitabine plu... TS-1 Gemcitabine | 20 Years - 79 Years | Taiho Pharmaceutical Co., Ltd. | |
| Gemox as First and Second Line Therapy in Unknown Primary Cancer | NCT00353145 | Unknown Primary... | Gemcitabine (Ge... Oxaliplatin Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors | NCT02715531 | Solid Tumor | 5-FU Atezolizumab Bevacizumab Gemcitabine Leucovorin Nab-Paclitaxel Oxaliplatin Capecitabine Cisplatin | 18 Years - | Hoffmann-La Roche | |
| A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer. | NCT05493995 | Pancreatic Neop... | Penpulimab Anlotinib Nab paclitaxel Gemcitabine | 18 Years - | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors | NCT01862328 | Solid Tumors | MLN4924 Paclitaxel Gemcitabine Docetaxel Carboplatin | 18 Years - | Takeda | |
| Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma | NCT02921022 | Pancreatic Canc... Advanced Pancre... | Gemcitabine Nab-paclitaxel PEGPH20 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer | NCT04909775 | Muscle-Invasive... | Tislelizumab Cisplatin Gemcitabine | 18 Years - 75 Years | Ruijin Hospital | |
| A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer | NCT01077713 | Non-Squamous No... | bevacizumab [Av... cisplatin gemcitabine gemcitabine | 70 Years - | Hoffmann-La Roche | |
| RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder | NCT01259063 | Bladder Cancer | Everolimus and ... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer | NCT01934634 | Metastatic Panc... | LCL161 Gemcitabine nab-Paclitaxel | 18 Years - | US Oncology Research | |
| Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma | NCT00429559 | Ovarian Cancer | Hycamptin Gemcitabine | 18 Years - 75 Years | Hellenic Oncology Research Group | |
| Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma | NCT01146054 | Pancreatic Canc... | CyberKnife base... Gemcitabine Fludeoxyglucose... | 18 Years - | Stanford University | |
| Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma | NCT01161186 | Pancreatic Neop... Pancreatic Canc... Adenocarcinoma | nab-paclitaxel,... | 18 Years - | University of California, San Francisco | |
| Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients | NCT00500422 | Solid Tumors | Doxil Gemcitabine Velcade | - | M.D. Anderson Cancer Center | |
| A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer | NCT00940875 | Non-Small Cell ... | erlotinib [Tarc... gemcitabine gemcitabine | 18 Years - | Hoffmann-La Roche | |
| Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT02446600 | Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... | Biospecimen Col... Carboplatin Cediranib Malea... Computed Tomogr... Echocardiograph... Gemcitabine Gemcitabine Hyd... Laboratory Biom... Magnetic Resona... Multigated Acqu... Olaparib Paclitaxel Pegylated Lipos... Pharmacological... Quality-of-Life... | 18 Years - | National Cancer Institute (NCI) | |
| QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas | NCT01231347 | Adenocarcinoma ... Advanced Solid ... Cancer Cancer of Pancr... Cancer of the P... Metastases Metastatic Canc... Metastatic Panc... Pancreas Cancer Pancreatic Canc... Bone Metastases Endocrine Cance... Oncology Oncology Patien... Solid Tumors Advanced Malign... | AMG 479 Placebo AMG 479 gemcitabine | 18 Years - | NantCell, Inc. | |
| Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma | NCT03984357 | Nasopharyngeal ... | PD-1 blocking a... Gemcitabine Cisplatin Intensity-modul... | 18 Years - 65 Years | Sun Yat-sen University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
